Alumis to Participate in Upcoming February Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will participate in the following investor conferences:

GlobeNewsWire • Feb 5, 2026

Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.

BML Capital Management sold 1,210,415 shares of Alumis in the fourth quarter. The shares were worth about $4.83 million as of the last-disclosed values.

The Motley Fool • Feb 3, 2026

Huge Insider Buying Now at This Insurance Giant and 2 Biotechs

In the past week, a beneficial owner has continued to build a stake in insurance giant W.R.

24/7 Wall Street • Jan 19, 2026

An Almus (ALMS) Insider Bought 588,000 Shares for $10.0 Million

Acquisition of 588,235 shares at $17.00 per share, representing a total transaction value of ~$10.0 million as of Jan. 9, 2026. This purchase represented 46.49% of Srinivas Akkaraju's previously reported indirect holdings.

The Motley Fool • Jan 17, 2026

Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the closing of its upsized underwritten public offering of 20,297,500 shares of its common stock, including the full exercise of the underwriters' option to purchase an additional 2,647,500 shares, at a price to the public of $17.00 per share.

GlobeNewsWire • Jan 9, 2026

Alumis Announces Pricing of Upsized Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the pricing of an upsized underwritten public offering of 17,650,000 shares of its common stock at a price to the public of $17.00 per share.

GlobeNewsWire • Jan 8, 2026

ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies

Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong skin clearance.

Zacks Investment Research • Jan 7, 2026

Alumis Up On Phase 3 Envudeucitinib Success: Oral Psoriasis Therapy Shows Promise

Alumis Inc. surged 95% after reporting strong Phase 3 results for lead candidate envudeucitinib in moderate-to-severe plaque psoriasis. Envudeucitinib demonstrated high efficacy for an oral agent, with two-thirds achieving PASI 90 and over 40% reaching complete clearance by Week 24. ALMS announced a $175 million public offering to fund regulatory and clinical advancement, with a 2026 NDA submission targeted.

Seeking Alpha • Jan 7, 2026

Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib

Investors today are cheering envudeucitinib's Phase 3 edge in oral TYK2 psoriasis as well as Alumis' plans to raise fresh capital.

The Motley Fool • Jan 6, 2026

Alumis skin disease drug meets main goal of two late-stage trials

Alumis said on Tuesday its experimental pill met the main goal in two late-stage studies in patients with a type of skin disease.

Reuters • Jan 6, 2026